8-K: Turning Point Brands Soars on Modern Oral Growth

Turning Point Brands reported strong Q4 and full-year 2025 results, driven by a 266% surge in Modern Oral net sales, despite declines in its Zig-Zag segment.

Summary

• Q4 2025 Modern Oral Net Sales increased 266% to $41.3 million, accounting for 34% of total company net sales, up from 12% in Q4 2024.
• Total Consolidated Net Sales increased 29.2% to $121.0 million in Q4 2025 and 28.4% to $463.1 million for the full year 2025.
• Adjusted EBITDA increased 14.4% to $30.0 million in Q4 2025 and 14.4% to $119.5 million for the full year 2025.
• Net Income increased 239.8% to $8.2 million in Q4 2025 and 46.1% to $58.2 million for the full year 2025.
• Stoker's segment Net Sales increased 69.5% in Q4 2025 and 69.1% for FY 2025, primarily due to triple-digit growth in Modern Oral sales.
• Zig-Zag segment Net Sales decreased 12.8% in Q4 2025 and 7.2% for FY 2025, attributed to the planned wind-down of the Clipper business and resource allocation to white pouch products.
• The company ended Q4 2025 with $222.8 million in cash and $77.2 million in net debt, with total liquidity of $290.1 million.
• Management provided FY 2026 guidance for Modern Oral Gross Revenue of $220-$240 million and Net Revenue of $180-$190 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance driven by exceptional growth in the Modern Oral segment, which is strategically positioned for future expansion, despite some declines in legacy brands. The robust financial metrics and positive outlook for the growth category contribute to a high sentiment score.

Positives

• Q4 2025 Modern Oral Net Sales surged 266% to $41.3 million, now comprising 34% of total company net sales, up from 12% in Q4 2024.
• Total Consolidated Net Sales increased 29.2% in Q4 2025 to $121.0 million and 28.4% for FY 2025 to $463.1 million.
• Q4 2025 Adjusted EBITDA grew 14.4% to $30.0 million, and FY 2025 Adjusted EBITDA grew 14.4% to $119.5 million.
• Net Income increased 239.8% in Q4 2025 to $8.2 million and 46.1% for FY 2025 to $58.2 million.
• Diluted EPS increased to $0.42 in Q4 2025 (from $0.13 in Q4 2024) and to $3.11 for FY 2025 (from $2.14 in FY 2024).
• Stoker's segment net sales increased 69.5% in Q4 and 69.1% for FY 2025, driven by triple-digit growth in Modern Oral sales.
• Strong liquidity position with $222.8 million in cash and $290.1 million total liquidity as of December 31, 2025.
• Management expects to achieve double-digit share of the modern oral category over time.

Negatives

• Zig-Zag segment Net Sales decreased 12.8% in Q4 2025 to $40.0 million and 7.2% for FY 2025 to $178.5 million, primarily due to declines in US sales.
• Stoker's segment gross margin decreased 115 basis points in Q4 2025 to 56.6% driven primarily by product mix.
• Zig-Zag segment gross margin declined 170 basis points for FY 2025 to 53.7%.
• Consolidated selling, general and administrative (SG&A) expenses increased 38.2% in Q4 2025 to $47.7 million, inclusive of Modern Oral-related sales and marketing investments and increased outbound freight costs.
• Non-cash asset impairment of $5.83 million was recorded in Q4 2025 and $6.738 million for the full year 2025.
• A mark-to-market loss of $0.153 million in Q4 2025 and $0.513 million for FY 2025 was attributable to foreign exchange fluctuation on a Canadian inter-company note.

Risks

• Forward-looking statements involve inherent risks and uncertainties, and actual events may differ materially from those expressed or suggested.
• The company cannot predict or identify all new risks and uncertainties that may arise and affect its performance.
• Preliminary financial estimates are subject to customary quarter-end closing and review procedures, and reported information in the Annual Report on Form 10-K may differ materially.
• Significant costs are associated with FDA Premarket Tobacco Product Application (PMTA) compliance, with $1.1 million in Q4 2025 and $4.816 million for FY 2025, which is a resource-intensive process for covered product lines.

Future Outlook

Management expects full year 2026 Modern Oral Gross Revenue to be between $220 million and $240 million, with Net Revenue projected at $180 million to $190 million. Q1 2026 adjusted EBITDA is anticipated to be $24 million to $27 million, including investments in Modern Oral sales, marketing, and trade promotions. The company aims to achieve a double-digit share of the modern oral category over time.

Management Comments

• "We are excited by the growth of the modern oral category and the strong performance of our FRE and ALP brands."
• "We are well positioned to achieve double-digit share of the category over time, while our legacy brands continue to generate durable cash flows that provide strong funding for investment in future growth."

Industry Context

StockSavvy.ai notes that the significant growth in Turning Point Brands' Modern Oral segment reflects a broader industry trend towards alternative nicotine products and reduced-risk tobacco alternatives. The company's strategic focus and investment in this category, as evidenced by the triple-digit growth, positions it to capitalize on evolving consumer preferences and regulatory landscapes, potentially gaining market share from traditional tobacco products. The decline in the Zig-Zag segment, while a negative, is framed as a strategic reallocation of resources, aligning with shifts in the broader market.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct comparison. StockSavvy.ai cannot provide a detailed assessment against global benchmarks without this information.

Legal Proceedings

• Costs of $1.1 million in Q4 2025 and $4.816 million for FY 2025 were incurred for FDA Premarket Tobacco Product Application (PMTA) related expenses to support the compliance roadmap for Modern Oral growth.
• Legal expenses were incurred in connection with litigation related to an insurance claim (amount not specified for Q4, $0.941 million for FY 2025).

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, significant growth in the Modern Oral segment, increased net income and EPS, and a positive future outlook for the growth category.
• Employees: Continued investment in Modern Oral sales and marketing may indicate job stability or growth in that segment, particularly for FRE and ALP brands.
• Customers: Expansion of Modern Oral products (FRE, ALP) suggests increased product availability and innovation in a growing market segment.
• Creditors: Improved financial health, strong cash position, and liquidity may enhance creditworthiness and reduce perceived risk.

Next Steps

• A conference call with the investment community is scheduled for 9:00 a.m. Eastern on Monday, March 2, 2026, to review the financial results.
• Continued investment in Modern Oral sales, marketing, and trade promotions is expected in Q1 2026.
• The company will complete its customary quarter-end closing and review procedures for the Annual Report on Form 10-K for the year ended December 31, 2025.

Key Dates

Recommendation

The company demonstrates exceptional growth in its Modern Oral segment, which is a high-growth market. Despite declines in legacy brands, the overall financial performance, including significant increases in net sales, net income, and adjusted EBITDA, indicates a successful strategic pivot. The strong liquidity and positive future outlook for the Modern Oral category suggest substantial upside potential for investors, warranting a strong buy recommendation.

Keywords

Turning Point Brands, TPB, Modern Oral, Stokers, Zig-Zag, FRE, ALP, Q4 2025 Earnings, Full Year 2025 Results, Adjusted EBITDA, Net Sales, Consumer Products, Alternative Smoking, SEC Filing, 8-K, Financial Results